During the recent session, Amicus Therapeutics Inc. (NASDAQ:FOLD)’s traded shares were 1.47 million, with the beta value of the company hitting 1.42. At the last check today, the stock’s price was $7.51, reflecting an intraday gain of 2.67% or $0.2. The 52-week high for the FOLD share is $12.63, that puts it down -68.18 from that peak though still a striking 21.3% gain since the share price plummeted to a 52-week low of $5.91. The company’s market capitalization is $2.16B, and the average intraday trading volume over the past 10 days was 6.29 million shares, and the average trade volume was 3.73 million shares over the past three months.
Amicus Therapeutics Inc. (FOLD) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.10. FOLD has a Sell rating from 0 analyst(s) out of 12 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 8 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.15.
Amicus Therapeutics Inc. (NASDAQ:FOLD) trade information
Amicus Therapeutics Inc. (FOLD) registered a 2.67% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.67% in intraday trading to $7.51 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is 10.42%, and it has moved by -12.77% in 30 days. Based on these gigs, the overall price performance for the year is -21.99%. The short interest in Amicus Therapeutics Inc. (NASDAQ:FOLD) is 24.08 million shares and it means that shorts have 7.65 day(s) to cover.
Amicus Therapeutics Inc. (FOLD) estimates and forecasts
Statistics show that Amicus Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Amicus Therapeutics Inc. (FOLD) shares have gone down -36.32% during the last six months, with a year-to-date growth rate more than the industry average at 3.26% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 44.40% this quarter and then jump 56.00% in the quarter after that. In the rating firms’ projections, revenue will increase 18.20% compared to the previous financial year.
Revenue for the current quarter is expected to be $84.77 million as predicted by 9 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $89.28 million by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $70.57 million and $66.4 million respectively. In this case, analysts expect current quarter sales to grow by 20.10% and then jump by 34.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 9.10%. While earnings are projected to return 13.70% in 2022.
Amicus Therapeutics Inc. is due to release its next quarterly earnings between February 28 and March 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Amicus Therapeutics Inc. (NASDAQ:FOLD)’s Major holders
Amicus Therapeutics Inc. insiders own 0.66% of total outstanding shares while institutional holders control 107.82%, with the float percentage being 108.53%. Perceptive Advisors Llc is the largest shareholder of the company, while 327 institutions own stock in it. As of Sep 29, 2021, the company held over 26.56 million shares (or 9.53% of all shares), a total value of $253.64 million in shares.
The next largest institutional holding, with 24.49 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 8.79% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $233.87 million.
Also, the Mutual Funds coming in first place with the largest holdings of Amicus Therapeutics Inc. (FOLD) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 7.54 million shares. This amounts to just over 2.71 percent of the company’s overall shares, with a $72.02 million market value. The same data shows that the other fund manager holds slightly less at 6.65 million, or about 2.39% of the stock, which is worth about $63.5 million.